This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: Q21.8 | Special Copayment Reduction: V226 (rare disease Special Copayment Reduction) |
| B. Synonyms | Eisenmenger defect, Eisenmenger syndrome, congenital heart disease–associated pulmonary arterial hypertension with irreversible pulmonary arterial hypertension (CHD-PAH) |
| C. Adult onset | Likelihood of first presentation in adulthood moderate to high — when a shunt congenital heart disease was diagnosed in infancy or childhood but corrective surgery was not performed, cyanosis and exercise intolerance often first become prominent in the 10s–30s with rising pulmonary vascular resistance and shunt reversal. Eisenmenger syndrome due to ASD may also appear in the 20s–40s. |
| 1. History | 1897: Eisenmenger's case report → 1958: Paul Wood established the concept of Eisenmenger syndrome → Heath-Edwards classification → 2000s: introduction of pulmonary hypertension–targeted therapies. |
| 2. Causes | Uncorrected left-to-right shunt congenital heart disease (VSD, ASD, PDA, AVSD, etc.) → pulmonary vascular remodeling → rising PVR → shunt reversal. Progression is rapid in AVSD with Down syndrome. |
| 3. Genetics | Follows the genetics of the underlying congenital heart disease. BMPR2 variants (associated with primary PAH). Patients with Down syndrome and AVSD: trisomy 21. |
| 4. General epidemiology | New cases decreasing with the spread of early repair. 1–5% of ACHD. Still a high proportion in low-income countries. Korea Q21.8, Special Copayment Reduction V226. |
| 5. Pathophysiology | Pulmonary vascular endothelial injury → smooth muscle proliferation → progression through Heath-Edwards I→VI. PVR ≥ SVR → reversal to right-to-left shunt → cyanosis. Polycythemia → increased risk of thrombosis. |
| 6. Symptoms | Cyanosis, clubbing, exercise intolerance (WHO FC I→IV). Hemoptysis, stroke, syncope, right heart failure. Symptoms of polycythemia (headache, visual disturbances). |
| 7. Signs | Cyanosis, clubbing, accentuated P2, diminished shunt murmur. Electrocardiogram: right ventricular hypertrophy. Chest X-ray: central PA dilation, peripheral vascular pruning. Echocardiography: increased TR Vmax, D-sign. |
| 8. Screening | Preventive screening: neonatal CCHD, prenatal fetal echocardiography, early correction of pediatric cardiac malformations. If already developed: regular echocardiography, BNP, 6MWT, blood tests. |
| 9. Diagnosis | Echocardiography (shunt reversal, right ventricular pressure, D-sign). Right heart catheterization (PVR ≥ 8 WU, negative vasoreactivity test). Confirmation of the underlying cardiac malformation. |
| 10. Treatment | Corrective surgery contraindicated. Pulmonary hypertension–targeted therapy (bosentan/BREATHE-5, sildenafil, macitentan, ERA+PDE-5i combination). Correction of iron deficiency. Phlebotomy (limited). End stage: heart-lung transplantation. |
| 11. Prognosis | Improved survival after introduction of targeted therapy (average 50s–60s). Sudden death, hemoptysis and stroke are the main causes of death. Pregnancy: maternal mortality risk 20–50%, strongly advised against. |
| 12. Prevention | Early correction of congenital heart disease (before irreversible pulmonary vascular progression). Early echocardiography and surgery in newborns with Down syndrome. Specialized management at ACHD centers, vaccination, preparedness for complications. |
| 13. References | List of 10 key references |
The history of Eisenmenger defect (Eisenmenger Defect/Syndrome) begins with a case report published in 1897 by the Austrian internist Victor Eisenmenger (1864–1932). At the autopsy of a cyanotic patient who died at age 32, Eisenmenger found a ventricular septal defect (VSD) and an overriding aorta, and described them as the cause of cyanosis due to a cardiac malformation. At the time, however, it was not recognized that pulmonary arterial hypertension was the core pathophysiology.
The turning point in modern understanding of this disease was the concept presented by Paul Wood in 1958. Wood defined as 'Eisenmenger syndrome' the state in which, in various left-to-right shunt congenital heart diseases, pulmonary vascular resistance rises to the systemic level so that the shunt reverses (right-to-left shunt) and cyanosis appears. This concept unified into a single syndrome the common final course of irreversible pulmonary arterial hypertension arising not only from VSD but from various shunt malformations such as ASD, PDA and AVSD.
In the 1960s–70s, the Heath-Edwards classification, a histologic staging of pulmonary vascular remodeling, was published and deepened understanding of pulmonary vascular lesions. Since the 1980s, as early surgical correction of congenital heart disease became widespread, new cases of Eisenmenger syndrome have decreased greatly. However, the syndrome still occurs in adult patients with delayed diagnosis and is a problem especially in low- and middle-income countries.
Since the 2000s, the development and use of pulmonary arterial hypertension–targeted therapies (epoprostenol, bosentan, sildenafil, macitentan, etc.) have contributed to improved quality of life and prolonged survival in patients with Eisenmenger syndrome. The 2022 European Society of Cardiology (ESC) pulmonary arterial hypertension guidelines recommend targeted therapy for Eisenmenger syndrome as Class I (level of evidence A). In Korea, a long-term management system for this disease has also been established, centered on specialized ACHD centers.
Eisenmenger defect does not refer to a specific congenital heart malformation but is a collective term for the state in which, in uncorrected left-to-right shunt congenital heart disease, pulmonary vascular resistance rises irreversibly and the shunt reverses. Causative congenital heart diseases include the following.
Ventricular septal defect (VSD): the most common cause; pulmonary arterial hypertension progresses fastest especially with large nonrestrictive VSDs. Atrial septal defect (ASD): occurs mainly with large secundum ASDs, and pulmonary arterial hypertension progresses later than with VSD (20s–40s). Patent ductus arteriosus (PDA): with a large PDA, pulmonary arterial hypertension progresses rapidly, similar to VSD. Atrioventricular septal defect (AVSD): rapid progression of pulmonary arterial hypertension is characteristic especially in complete AVSD with Down syndrome. Others: aortopulmonary septal defect (APSD), truncus arteriosus, etc.
The mechanism of rising pulmonary vascular resistance begins with pulmonary vascular endothelial injury from persistently increased pulmonary blood flow and pressure load. As endothelial dysfunction, smooth muscle proliferation and vascular remodeling progress, pulmonary vascular structure changes through Heath-Edwards stages I→II→III→IV. At grades III–IV the lesions are irreversible, so pulmonary arterial hypertension persists even if the causative malformation is corrected. After this point, corrective surgery is actually fatal because removing the shunt causes an abrupt increase in right ventricular afterload.
Because Eisenmenger defect (Eisenmenger syndrome) is not an isolated genetic disease but a complication state of various congenital heart diseases, its genetics follow those of the underlying congenital heart disease.
The genetic backgrounds of the congenital heart diseases that cause Eisenmenger syndrome are diverse. Eisenmenger syndrome due to VSD: genetic causes of VSD (NKX2.5, GATA4, TBX20, 22q11.2 deletion, etc.). Due to ASD: GATA4, TBX5, NKX2.5 variants. AVSD with Down syndrome: trisomy 21. Patients with Down syndrome have stronger than normal pulmonary vascular reactivity, so progression to Eisenmenger syndrome is rapid, and hypoxic pulmonary vasoconstriction further accelerates progression.
A genetic predisposition to pulmonary arterial hypertension itself may also influence the rate of progression of Eisenmenger syndrome in some patients. BMPR2 (bone morphogenetic protein receptor type 2) variants are the main causative gene of primary pulmonary arterial hypertension, and the possibility that these variants also partly influence the rate of progression of congenital heart disease–associated pulmonary arterial hypertension has been raised at the research stage. In all patients with Eisenmenger syndrome, accurate diagnosis and genetic evaluation of the underlying congenital heart disease are needed for family counseling.
Eisenmenger syndrome is a complication state arising in congenital heart disease patients who did not undergo corrective surgery, so its true prevalence is difficult to determine. As early surgical correction of congenital heart disease has spread worldwide, new cases of Eisenmenger syndrome have decreased greatly. In ACHD cohorts in developed countries, patients with Eisenmenger syndrome are reported to account for about 1–5% of all ACHD patients.
In Korea, there are patients classified as Q21.8 (Eisenmenger defect) and registered under Special Copayment Reduction V226, who are eligible for rare disease medical cost support. However, many patients are registered under the ICD code of the underlying congenital heart disease, so determination of the actual national prevalence of Eisenmenger syndrome is incomplete.
In low- and middle-income countries, the proportion of patients with Eisenmenger syndrome remains high because of insufficient access to diagnosis and surgery for congenital heart disease. The World Health Organization (WHO) and the World Heart Federation (WHF) identify this problem as a key challenge in congenital heart disease care in low-income countries. Systematic follow-up of patients with Eisenmenger syndrome and improved access to pulmonary arterial hypertension–targeted therapy are needed at specialized ACHD centers in Korea.
The pathophysiology of Eisenmenger syndrome is understood as centering on shunt reversal due to pulmonary vascular remodeling and rising pulmonary vascular resistance. Initially, the left-to-right shunt increases pulmonary blood flow, and high shear stress and pressure persist in the pulmonary vessels.
Persistent pulmonary vascular endothelial injury → endothelial cell dysfunction (reduced endothelium-dependent vasodilation, increased vasoconstrictor factors) → pulmonary vascular smooth muscle proliferation → intimal and medial thickening → pulmonary artery thrombus formation → progression to vascular dropout. Heath-Edwards histologic classification: grade I (no intimal thickening, medial hypertrophy), grade II (intimal cellular proliferation), grade III (intimal fibrotic occlusion), grades IV–VI (complex lesions, dilatation lesions, necrotizing arteritis), with progression of irreversible changes.
When pulmonary vascular resistance exceeds systemic vascular resistance, the shunt reverses (right-to-left shunt), deoxygenated blood enters the systemic circulation and cyanosis appears. As a compensatory response to chronic cyanosis, polycythemia develops, increasing blood viscosity and raising the risk of thrombosis. At the same time, iron stores consumed by excessive red cell production decrease, and functional iron deficiency can develop, which is a risk factor for stroke.
The clinical symptoms of Eisenmenger syndrome consist of various symptoms arising from chronic cyanosis and pulmonary arterial hypertension.
Cyanosis and related symptoms: worsening cyanosis with exercise, cyanosis even at rest (severe pulmonary arterial hypertension) and clubbing appear. Exercise intolerance gradually worsens, progressing through WHO functional class II→III→IV. Headache, dizziness and syncope occur due to increased blood viscosity from polycythemia or reduced pulmonary blood flow.
Bleeding complications: hemoptysis, due to pulmonary vessel rupture or thrombosis, is a life-threatening complication. Mucosal bleeding such as epistaxis and gum bleeding may also occur. Thrombotic complications: pulmonary thrombosis, cerebral thrombosis (risk of stroke due to polycythemia). Heart failure symptoms: dyspnea, orthopnea, leg edema (right heart failure). Arrhythmias: atrial fibrillation, atrial flutter, ventricular tachycardia.
Cyanosis and clubbing are characteristic physical findings. The shunt murmur at the left sternal border is diminished or absent, and P2 (the pulmonic valve closure sound) is accentuated (loud P2). A tricuspid regurgitation murmur and a pulmonary regurgitation murmur (Graham-Steell murmur) may be heard.
Electrocardiogram: right axis deviation, right ventricular hypertrophy. Chest X-ray: central pulmonary artery dilation, decreased peripheral pulmonary vascular markings ("pruning"), right ventricular and right atrial enlargement. Echocardiography: elevated right ventricular pressure (increased TR Vmax, estimated pulmonary artery pressure), right ventricular hypertrophy, dilation and dysfunction, reversed shunt direction (right-to-left), flattening of the ventricular septum (D-sign). Elevated BNP/NT-proBNP is an indicator of the severity and prognosis of right heart failure.
6-minute walk test (6MWT) and cardiopulmonary exercise testing: used to assess exercise capacity and track treatment response. Blood tests: erythrocytosis (increased hematocrit), thrombocytopenia, increased serum uric acid, markers of iron deficiency (microcytosis, low serum ferritin).
Because Eisenmenger syndrome occurs when the opportunity to correct the underlying congenital heart disease has been missed, preventive screening is achieved through early diagnosis and early correction of the underlying congenital heart disease. Neonatal CCHD oxygen saturation screening, prenatal fetal echocardiography and echocardiography in pediatric health checkups are the key preventive screening tools.
In established Eisenmenger syndrome, regular echocardiography for assessing the severity of pulmonary arterial hypertension (estimated right ventricular pressure, ventricular function), BNP/NT-proBNP, 6-minute walk distance, arterial blood gas analysis and blood tests (erythrocytosis, iron deficiency, platelets) are performed as periodic screening and follow-up tests. Cardiac catheterization is performed to measure pulmonary vascular resistance when deciding on a treatment plan.
The diagnosis of Eisenmenger syndrome consists of identifying the underlying congenital heart disease, assessing the degree and irreversibility of pulmonary arterial hypertension, and confirming reversal of shunt direction.
Echocardiography is the key test for identifying the underlying congenital heart disease (VSD, ASD, PDA, etc.) and assessing shunt direction (right-to-left reversal), estimated right ventricular pressure (TR Vmax), right ventricular size and function, and flattening of the ventricular septum (D-shape). When the estimated pulmonary artery pressure shows systolic pulmonary artery pressure ≥ systemic pressure, Eisenmenger syndrome is strongly suggested.
Cardiac catheterization: right heart catheterization measures pulmonary artery pressure, pulmonary vascular resistance (PVR), mixed venous oxygen saturation and the pulmonary-to-systemic flow ratio (Qp/Qs). If PVR is ≥ 8 Wood units (or ≥ 2/3 or more of systemic vascular resistance) and there is no response on vasoreactivity testing (oxygen, iNO), the pulmonary arterial hypertension is judged irreversible. In this case, corrective surgery of the underlying cardiac malformation is contraindicated.
Because the pulmonary vascular lesions in Eisenmenger syndrome are irreversible, surgical correction of the underlying congenital heart disease is contraindicated. The goals of treatment are improved quality of life, symptom relief and prolonged survival.
Pulmonary arterial hypertension–targeted therapies: endothelin receptor antagonists (ERA: bosentan, macitentan, ambrisentan), phosphodiesterase-5 inhibitors (PDE-5i: sildenafil, tadalafil), guanylate cyclase stimulators (riociguat), prostacyclin analogues (epoprostenol, treprostinil, iloprost) and others are used. The efficacy of bosentan in Eisenmenger syndrome was demonstrated in the BREATHE-5 trial. Combination therapy with these drugs may be more effective than monotherapy.
Correction of iron deficiency: in functional iron deficiency, iron supplementation (oral or intravenous) is important for preventing neurologic complications (stroke). Management of polycythemia: limited phlebotomy is performed only when hematocrit is > 65% or higher and there are symptoms (headache, visual disturbances, etc.), with replacement by an equal volume of saline. Heart-lung transplantation, or lung transplantation with simultaneous correction of the cardiac malformation, is the last option in end-stage patients.
Eisenmenger syndrome formerly had a very poor prognosis, but survival is improving with the introduction of pulmonary arterial hypertension–targeted therapies. In reports before targeted therapy, the average age at survival of patients with Eisenmenger syndrome was in the 30s–40s, but recent studies show increasing cases of survival into the 50s–60s.
The main causes of death are sudden death, congestive heart failure, stroke, infectious complications and hemoptysis. WHO functional class III–IV, short 6-minute walk distance, high BNP/NT-proBNP, increased serum uric acid and iron deficiency are poor prognostic indicators. Pregnancy in Eisenmenger syndrome carries a very high risk of maternal death (20–50%), so pregnancy is strongly advised against. Interestingly, there are study results showing that patients with Eisenmenger syndrome associated with Down syndrome have better survival than non-syndromic patients.
The best prevention of Eisenmenger syndrome is early diagnosis of the underlying congenital heart disease and performing corrective surgery before pulmonary vascular damage progresses irreversibly (within a few months to 2 years after birth).
The key preventive strategy is early detection of large shunt congenital heart diseases through prenatal fetal echocardiography and neonatal CCHD screening, and immediate linkage to specialized pediatric cardiology care. In newborns with Down syndrome, early echocardiography and, after identification of cardiac malformations such as complete AVSD, corrective surgery within 3–4 months after birth are key to preventing progression to Eisenmenger syndrome. When Eisenmenger syndrome has developed in adulthood, comprehensive care is provided at a specialized ACHD center, including pulmonary arterial hypertension–targeted therapy, infection prevention (influenza and pneumococcal vaccination), management of acute complications such as hemoptysis, stroke and heart failure, counseling on the contraindication of pregnancy, and transplant evaluation.
Wood P. The Eisenmenger syndrome or pulmonary hypertension with reversed central shunt. Br Med J. 1958;2(5099):701-709. DOI: 10.1136/bmj.2.5099.701. PMID: 13572874.
Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2016;37(1):67-119. DOI: 10.1093/eurheartj/ehv317. PMID: 26320113.
Galiè N, Beghetti M, Gatzoulis MA, et al. Bosentan therapy in patients with Eisenmenger syndrome (BREATHE-5). Circulation. 2006;114(1):48-54. DOI: 10.1161/CIRCULATIONAHA.106.630715. PMID: 16801464.
Diller GP, Gatzoulis MA. Pulmonary vascular disease in adults with congenital heart disease. Circulation. 2007;115(8):1039-1050. DOI: 10.1161/CIRCULATIONAHA.106.655720. PMID: 17325254.
Kaemmerer H, Gorenflo M, Huscher D, et al. Treatment and outcome of adults with Eisenmenger syndrome and pulmonary arterial hypertension. Int J Cardiol. 2020;306:157-164. DOI: 10.1016/j.ijcard.2019.12.030. PMID: 32008767.
Oechslin E, Kiowski W, Schindler R, Bernheim A, Julius B, Lipp E. Systemic endothelin-1 plasma levels in cyanotic patients with congenital heart disease and pulmonary arterial hypertension. J Am Coll Cardiol. 2005;46(7):1344-1348. DOI: 10.1016/j.jacc.2005.05.076. PMID: 16198855.
Hopkins WE, Ochoa LL, Richardson GW, Trulock EP. Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome. J Heart Lung Transplant. 1996;15(1 Pt 1):100-105. PMID: 8820085.
Diller GP, Alonso-Gonzalez R, Dimopoulos K, et al. Disease targeting therapies in patients with Eisenmenger syndrome: response to treatment and long-term efficiency. Int J Cardiol. 2013;167(3):840-847. DOI: 10.1016/j.ijcard.2012.02.007. PMID: 22402065.
Stout KK, Daniels CJ, Aboulhosn JA, et al. 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease. J Am Coll Cardiol. 2019;73(12):e81-e192. DOI: 10.1016/j.jacc.2018.08.1029. PMID: 30121239.
Dimopoulos K, Diller GP, Koltsida E, et al. Prevalence, predictors, and prognostic value of renal dysfunction in adults with congenital heart disease. Circulation. 2008;117(18):2320-2328. DOI: 10.1161/CIRCULATIONAHA.107.734921. PMID: 18427132.